Widely used:Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹1,882 Cr
Revenue (TTM)
₹760 Cr
Net Profit (TTM)
₹61 Cr
ROE
13.8 %
ROCE
18.3 %
P/E Ratio
30.9
P/B Ratio
3.7
Industry P/E
36.76
EV/EBITDA
16.9
Div. Yield
0.6 %
Debt to Equity
0
Book Value
₹241.3
EPS
₹29.2
Face value
5
Shares outstanding
20,959,311
CFO
₹272.61 Cr
EBITDA
₹433.52 Cr
Net Profit
₹265.00 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Windlas Biotech
| -13.7 | -6.1 | 2.9 | 24.0 | 62.1 | -- | -- |
|
BSE Healthcare
| -4.5 | 1.7 | 8.6 | 15.7 | 27.1 | 21.7 | 10.5 |
|
BSE Small Cap
| -3.2 | 3.9 | 21.0 | 3.6 | 30.0 | 34.8 | 17.3 |
|
Company
|
2024
|
2023
|
2022
|
|---|---|---|---|
|
Windlas Biotech
| 118.5 | 71.4 | -9.4 |
|
BSE Small Cap
| 29.0 | 47.5 | -1.8 |
|
BSE Healthcare
| 43.1 | 37.0 | -12.1 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Windlas Biotech
|
898.3 | 1,881.7 | 759.9 | 61.0 | 8.7 | 12.5 | 30.9 | 3.7 |
| 718.4 | 2,072.0 | 451.8 | 50.8 | 11.4 | 16.3 | 40.8 | 6.3 | |
| 468.4 | 7,638.2 | 2,108.1 | 266.8 | 12.5 | 11.7 | 28.6 | 3.3 | |
| 363.2 | 3,636.1 | 819.8 | 69.7 | 13.9 | 11.9 | 52.2 | 6.0 | |
| 428.8 | 2,621.5 | 559.1 | -8.7 | -10.9 | -159 | -- | 3.1 | |
| 5,951.0 | 9,886.6 | 1,218.1 | 251.2 | 28.1 | -- | 39.4 | 18.4 | |
| 917.9 | 8,994.8 | 1,286.4 | 79.6 | 15.9 | 4.7 | 114.9 | 3.8 | |
| 853.8 | 7,873.5 | 4,632.7 | 358.2 | 14.8 | 15 | 2.2 | 3.1 | |
| 670.9 | 5,392.8 | 696.5 | 188.0 | 34.5 | 19.8 | 28.7 | 5.4 | |
| 19.3 | 1,817.0 | 466.0 | 49.4 | 10.7 | 15.1 | 36.8 | 5.3 |
Sigachi Industries IPO: Information analysis
6 min read•By Arul Selvan and Udhayaprakash
3 min read•By Udhayaprakash
6 min read•By Arul Selvan
Windlas Biotech Limited, a contract development and manufacturing organization (CDMO), manufactures and trades in pharmaceutical products in India and internationally. The company offers CDMO services, including product discovery, product... development, licensing, and commercial manufacturing of generic products. It manufactures nutraceutical supplement products. In addition, the company manufactures tablets, capsules, pouches, sachets, and liquid bottles; and generic products portfolio comprises fixed dosage combinations, fixed dosage plus modified release combinations, customized generics, and chewable or dispersible. The company was incorporated in 2001 and is based in Gurugram, India. Read more
Incorporated
2001
Chairman
Vivek Dhariwal
Managing Director
Hitesh Windlass
Headquarters
Dehradun, Uttarakhand
Website
Looking for more details about Windlas Biotech Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The total asset value of Windlas Biotech Ltd stood at ₹ 760 Cr as on 31-Mar-25
The share price of Windlas Biotech Ltd is ₹898.30 (NSE) and ₹897.80 (BSE) as of 18-Jun-2025 IST. Windlas Biotech Ltd has given a return of 62.06% in the last 3 years.
Windlas Biotech Ltd has a market capitalisation of ₹ 1,882 Cr as on 18-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Windlas Biotech Ltd is 3.72 times as on 18-Jun-2025, a 30% discount to its peers’ median range of 5.31 times.
The P/E ratio of Windlas Biotech Ltd is 30.85 times as on 18-Jun-2025, a 16% discount to its peers’ median range of 36.76 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Windlas Biotech Ltd and enter the required number of quantities and click on buy to purchase the shares of Windlas Biotech Ltd.
Windlas Biotech Limited, a contract development and manufacturing organization (CDMO), manufactures and trades in pharmaceutical products in India and internationally. The company offers CDMO services, including product discovery, product development, licensing, and commercial manufacturing of generic products. It manufactures nutraceutical supplement products. In addition, the company manufactures tablets, capsules, pouches, sachets, and liquid bottles; and generic products portfolio comprises fixed dosage combinations, fixed dosage plus modified release combinations, customized generics, and chewable or dispersible. The company was incorporated in 2001 and is based in Gurugram, India.
The prominent promoters of Windlas Biotech Ltd. are
| Name of promoters | Holding percentage |
|---|---|
|
AKW WBL Family Private Trust (through its Trustees Ashok Vimla Trusteeship Services Private Limited) |
39.99%
|
|
Ashok Kumar Windlass |
20.99%
|
|
Vimla Windlass |
1.36%
|
The chairman of the company is Vivek Dhariwal, and the managing director is Hitesh Windlass.
There is no promoter pledging in Windlas Biotech Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
9,692
|
|
|
9,644
|
|
|
8,142
|
|
|
7,752
|
|
|
5,552
|
|
|
3,729
|
|
|
2,767
|
|
|
2,021
|
|
|
2,017
|
| Windlas Biotech Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
12.49
|
|
Operating margin(%)
|
8.7
|
|
Net Margin(%)
|
7.84
|
|
Dividend yield(%)
|
0.65
|
Yes, TTM profit after tax of Windlas Biotech Ltd was ₹61 Cr.
₹-13.70
(
